SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc.
Myriad Genetics, Inc. MYGN recently announced an agreement to enhance education and access to hereditary cancer testing for CancerCARE for Life members. Under the agreement, more than 1 million ...
Myriad Genetics, Inc. (MYGN), a genetic and genomic tumor testing and precision medicine provider, and INTERLINK Care Management, ...
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ ... tests — Prolaris ® Prostate Cancer Test and MyRisk ® Hereditary Cancer Test – into Lumea’s digital ...
Myriad Genetics. “Expanding access through CancerCARE’s network will give more patients the opportunity to take the MyRisk with RiskScore Hereditary Cancer Test.” MyRisk with RiskScore is ...
Patients who take the MyRisk test can then review their results with a Myriad genetic counselor. Myriad's Breast Cancer Risk Assessment Program features the MyRisk with RiskScore Hereditary Cancer ...
“MyRisk’s clear, actionable results provide the foundation for personalized care plans, empowering patients to make confident, informed decisions about their medical management,” said Melissa Gonzales ...